Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Cardiff-based Biodexa Pharmaceuticals PLC has announced a significant change in the nominal value of its ordinary shares. The pharmaceutical company, known for its specialization in pharmaceutical preparations, has reduced the nominal value from £0.00005 per share to £0.000001 per share, a move approved by shareholders at a general meeting on June 11, 2025.
This decision is part of the adoption of new Articles of Association, which are now available as Exhibit 1.1 in the company’s latest report to the Securities and Exchange Commission (SEC). The document details the changes and is incorporated by reference into the company’s registration statements on Form S-8 and Form F-3.
Biodexa Pharmaceuticals, previously known as Midatech Pharma Plc until a name change on June 2, 2015, has made this adjustment as per the regulatory filing submitted today. The filing, a Form 6-K, is a requirement for foreign private issuers to provide the SEC with updates on significant corporate events.
The company’s CEO and CFO, Stephen Stamp, has signed off on the report, ensuring compliance with the Securities Exchange Act of 1934. Biodexa’s business address remains at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (TADAWUL:4280), with the same contact number for official communications.
This change in share nominal value is now part of the official record and will be reflected in the company’s future financial documentation. Investors and stakeholders are encouraged to review the new Articles of Association to understand the implications of this amendment fully. This information is based on a press release statement provided by Biodexa Pharmaceuticals PLC to the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.